Adverse events (proportion) (12 months) · people with acute HBV infection
It is very uncertain whether lamivudine changes adverse events (proportion) (12 months) compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events (number of events) (12 months) · people with acute HBV infection
It is very uncertain whether lamivudine changes adverse events (number of events) (12 months) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life (1 week) · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term mortality · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to chronic HBV infection · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether colchicine changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether colchicine changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether insulin plus glucagon changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether insulin plus glucagon changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether propylthiouracil changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found